SOPHiA GENETICS S.A. Q4 2025 Earnings Call Summary

1 week ago 3

Moby Intelligence

Tue, March 3, 2026 astatine 11:34 AM CST 3 min read

SOPHiA GENETICS S.A. Q4 2025 Earnings Call Summary

SOPHiA GENETICS S.A. Q4 2025 Earnings Call Summary - Moby
  • Achieved 22% full gross maturation successful Q4 2025, driven by a 31% summation successful objective gross arsenic the halfway concern re-accelerated toward humanities levels.

  • Processed astir 1 petabyte of genomic information successful 2025, doubling measurement from 2 years agone owed to a marketplace displacement toward ample broad panels and multi-omic analysis.

  • Expanded adjusted gross borderline by 140 ground points to 74.2% done a large architectural modernization that accrued compute capableness tenfold and reduced full genome investigation clip to nether 6 hours.

  • Secured 2 of the largest integrated wellness systems successful the US, representing a combined imaginable of 60,000 yearly genomic tests and 1 cardinal oncology/rare illness patients.

  • Maintained precocious level stickiness with annualized gross churn beneath 1% and a Net Promoter Score of 67, validating the decentralized AI deployment model.

  • Announced a enactment modulation with Ross Muken to go CEO successful July 2026, portion laminitis Jurgi Camblong moves to Executive Chairman to absorption connected method innovation.

  • Leveraged a divers information watercourse from 75 countries to motorboat 'Digital Twins' for lung cancer, enabling AI-driven virtual simulations for therapy selection.

  • Projecting 2026 gross betwixt $92 cardinal and $94 million, with maturation heavy back-half weighted arsenic grounds 2025 bookings modulation to regular usage.

  • Management anticipates a nett affirmative biopharma publication successful 2026 arsenic their communicative begins to resonate with elder members of apical 20 pharmaceutical companies, though they are not yet forecasting a melodramatic acceleration oregon 'hockey stick' maturation for that year.

  • Targeting adjusted EBITDA breakeven by the extremity of 2026 and affirmative adjusted EBITDA successful the 2nd fractional of 2027 by dropping 60% of incremental gross to the bottommost line.

  • Assuming continued ASP enlargement arsenic customers migrate to higher-value products similar MSK-ACCESS and Enhanced Exomes, contempt lower-ASP measurement maturation successful emerging markets.

  • Planning to clasp operating expenses level successful section currency by flattening organizational structures and optimizing discretionary spending.

  • Reported important adverse overseas speech impacts owed to a 14% appreciation of the Swiss franc, which inflated payroll and rent expenses successful US dollar terms.

  • Incurred $1.8 cardinal successful ineligible expenses related to patent litigation with Guardant Health; however, the Unified Patent Court precocious rejected Guardant's petition for provisional measures.

  • Strengthened liquidity by raising $15.5 cardinal done an ATM installation and expanding a recognition installation with Perceptive Advisors by $25 million.

  • Identified a grounds debased nett dollar retention of 115%, up from 104% successful the anterior year, driven by palmy cross-selling of further objective applications.

Read Entire Article